Literature DB >> 35525547

Conformational control and regulation of the pseudokinase KSR via small molecule binding interactions.

Arthur Chow1, Zaigham M Khan1, William M Marsiglia1, Arvin C Dar2.   

Abstract

Pseudokinases often operate through functionally related enzymes and receptors. A prime example is the pseudokinase KSR (Kinase Suppressor of RAS), which can act as both an amplifier and inhibitor of members in the RAS-MAPK (Mitogen Activated Protein Kinase) signaling pathway. KSR is structurally related to the active RAF kinases over multiple domains; moreover, the pseudokinase domain of KSR forms physical and regulatory complexes with both RAF and MEK through distinct interfaces. Characterization of small molecule interactions on KSR has been used to uncover novel chemical tools and understand the mechanism of action of clinical drugs. Here, we elaborate on assays and structural methods for measuring binding at orthosteric and interfacial binding sites on KSR. These distinct small molecule pockets provide therapeutic paths for targeting KSR1 and KSR2 pseudokinases in disease, including in RAS and RAF mutant cancers.
Copyright © 2022 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Activity-based probes; Crystallization; Interfacial sites; KSR; MEK; Molecular glues; Orthosteric site; RAF; SBDD; Target engagement

Mesh:

Substances:

Year:  2022        PMID: 35525547      PMCID: PMC9150438          DOI: 10.1016/bs.mie.2022.03.039

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.682


  69 in total

1.  Recombinant protein expression in baculovirus-infected insect cells.

Authors:  Donald L Jarvis
Journal:  Methods Enzymol       Date:  2014       Impact factor: 1.600

2.  Mutation that blocks ATP binding creates a pseudokinase stabilizing the scaffolding function of kinase suppressor of Ras, CRAF and BRAF.

Authors:  Jiancheng Hu; Haiyang Yu; Alexandr P Kornev; Jianping Zhao; Erin L Filbert; Susan S Taylor; Andrey S Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-03-25       Impact factor: 11.205

3.  Dimerization Induced by C-Terminal 14-3-3 Binding Is Sufficient for BRAF Kinase Activation.

Authors:  Nicholas P D Liau; Avinashnarayan Venkatanarayan; John G Quinn; Wilson Phung; Shiva Malek; Sarah G Hymowitz; Jawahar Sudhamsu
Journal:  Biochemistry       Date:  2020-10-02       Impact factor: 3.162

4.  Complex formation between RAS and RAF and other protein kinases.

Authors:  L Van Aelst; M Barr; S Marcus; A Polverino; M Wigler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-07-01       Impact factor: 11.205

5.  Type II Binders Targeting the "GLR-Out" Conformation of the Pseudokinase STRADα.

Authors:  Ryan H B Smith; Zaigham M Khan; Peter Man-Un Ung; Alex P Scopton; Lisa Silber; Seshat M Mack; Alexander M Real; Avner Schlessinger; Arvin C Dar
Journal:  Biochemistry       Date:  2021-01-13       Impact factor: 3.162

6.  Kinase suppressor of Ras (KSR) is a scaffold which facilitates mitogen-activated protein kinase activation in vivo.

Authors:  AnhCo Nguyen; W Richard Burack; Jeffrey L Stock; Robert Kortum; Oleg V Chaika; Maryam Afkarian; William J Muller; Kenneth M Murphy; Deborah K Morrison; Robert E Lewis; John McNeish; Andrey S Shaw
Journal:  Mol Cell Biol       Date:  2002-05       Impact factor: 4.272

7.  KSR modulates signal propagation within the MAPK cascade.

Authors:  M Therrien; N R Michaud; G M Rubin; D K Morrison
Journal:  Genes Dev       Date:  1996-11-01       Impact factor: 11.361

8.  The protein kinase KSR interacts with 14-3-3 protein and Raf.

Authors:  H Xing; K Kornfeld; A J Muslin
Journal:  Curr Biol       Date:  1997-05-01       Impact factor: 10.834

9.  KSR, a novel protein kinase required for RAS signal transduction.

Authors:  M Therrien; H C Chang; N M Solomon; F D Karim; D A Wassarman; G M Rubin
Journal:  Cell       Date:  1995-12-15       Impact factor: 41.582

10.  Disruption of CRAF-mediated MEK activation is required for effective MEK inhibition in KRAS mutant tumors.

Authors:  Piro Lito; Anna Saborowski; Jingyin Yue; Martha Solomon; Eric Joseph; Sunyana Gadal; Michael Saborowski; Edward Kastenhuber; Christof Fellmann; Kazuhiro Ohara; Kenji Morikami; Takaaki Miura; Christine Lukacs; Nobuya Ishii; Scott Lowe; Neal Rosen
Journal:  Cancer Cell       Date:  2014-04-17       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.